Drug Discovery

Harbour BioMed signs $350m deal with Kelun-Biotech for ex-China rights to A167

Harbour BioMed and Sichuan Kelun-Biotech Biopharmaceutical (Kelun-Biotech) have entered into a partnership to develop and commercialize the latter’s A167, an anti-PD-L1 antibody, for the treatment of cancer.

Study finds new drug treatment could reduce liver transplants

Scientists in the UK believe that patients with sudden liver failure could benefit from a new treatment in the future that could cut down the need for transplants by preventing a process called senescence with certain anti-cancer therapy drugs.

AbbVie, Tolero to collaborate on acute myeloid leukemia trial

AbbVie has entered into clinical research collaboration with Tolero Pharmaceuticals to assess the potential benefits of venetoclax and alvocidib combination in relapsed/refractory acute myeloid leukemia (AML).

WuXi AppTec, Cyclica collaborate to advance drug discovery programs

WuXi AppTec ‘s research service division and Cyclica have announced a multi-phase collaboration to advance drug discovery programs by driving insights into small molecule polypharmacology, while further evolving Cyclica’s biophysics and AI-augmented platform.

Pfizer, BioNTech to develop mRNA-based vaccines for influenza

Biotechnology firm BioNTech has collaborated with Pfizer for the development of mRNA-based vaccines to prevent influenza (flu).

Haplogen, Bayer enter into drug discovery and development collaboration

Haplogen and German pharma firm Bayer have entered into a collaboration to develop drug candidates for the treatment of chronic obstructive pulmonary disease (COPD) and other pulmonary diseases.

Orchard Therapeutics raises $150m to advance gene therapies for rare diseases

Orchard Therapeutics, a biotechnology company focused on developing gene therapies for rare diseases, has raised $150m through a Series C funding round.

Aralez Pharmaceuticals agrees to sell main operating businesses

Canadian specialty pharmaceutical firm Aralez Pharmaceuticals has entered into two separate agreements to sell substantially all of its assets for a total of $250m.

Therachon raises $60m to expand rare disease pipeline

Clinical-stage biotechnology firm Therachon has raised $60m mezzanine financing to advance lead program in achondroplasia and expand rare disease pipeline.